Nanopharma – Discover Revenue Prospects Now, Benefiting Your Authority Do you want to find sales potentials of nanomedicine? If so, our new analysis gives you revenue forecasts to 2025 at overall world market, application, product and national level. That way you discover financial data, trends, R&D, opportunities and commercial outlooks.
Visiongain’s study gives you revenue predictions from 2015 for nano-enabled drugs. There you explore trends, technologies and expected products, benefiting your reputation for technological and commercial insight. Discover what the future holds, staying ahead.
Our work explains the potential of nanomedicine to change pharma. See how those developments affect patients, healthcare providers and pharmaceutical companies.
Please read on to explore what drives and shapes that industry, also seeing revenue prediction.
Forecasts and other analysis show you where the best sales opportunities exist Our new report shows revenue forecasting to 2025, recent results, growth rates and market shares. You explore quantitative and qualitative analyses, business news, research and development. You gain 34 tables, 44 charts and three interviews with other experts.
With that study you assess clinical, technological and commercial trends, results and potentials: • Why will the nanopharma market expand fast – and what future revenues are possible? • When will that worldwide industry achieve overall sales in hundreds of billion dollars? • What products give the most promise for developers, producers and sellers? • Who are the best-placed companies in that healthcare industry from 2015? • Where are the most lucrative regions for selling those medicines? • How will nanotechnological advances affect drug developers, marketers and manufacturers?
Many opportunities exist in healthcare for applications of nanotechnology. With our study you discover what segments are most likely to prosper. See potential sales from 2015.
Why struggle to find data, losing time and missing out? Instead help your research, analyses, plans, proposals and presentations. With our research and analysis, see how to save time and benefit your authority on nanomedicine.
That way you explore what the future holds for nanopharma. The following sections outline how our new investigation helps your work.
Predictions for that world market and submarkets – what sales growth is possible? Along with revenue prediction for the overall world market for nanopharmaceuticals, our investigation shows you forecasts to 2025 for six individual therapeutic submarkets: • Cancer • Cardiovascular disorders • Central nervous system (CNS) conditions • Infectious diseases • Inflammation • Other applications of nanotechnology in pharmacotherapy.
Our report analyses sales potentials of those technological advances, showing how companies gain. That work can also benefit your authority on nanomedical applications, expanding your reputation for commercial and technological knowledge.
The new investigation discusses what stimulates and restrains sales of those treatments. You explore that industry, also seeing what products can achieve the most success.
Forecasting of leading products’ sales – what revenues are possible for nanodrugs? How will individual medicines perform from 2015 to 2025 at world level? Our study forecasts revenues of 13 brands: • Abraxane • Alimta • Eligard • Copaxone • Rapamune • Neulasta • Cimzia.
Our sales predictions also cover these products: • AmBisome • MIRCERA • Pegasys • Emend • Renagel • Ritalin.
That work shows how high sales can go, revealing drugs and years with highest predicted revenues. You also examine competition. That way you investigate what is happening, understanding challenges, trends, R&D, competitors and opportunities.
Discover what the future holds. Our study also divides its overall world forecast into geographical segments.
Regional markets for nanomedicine – where will highest sales and growth occur? Developments worldwide will influence the nano-enabled drugs market, raising demand for those therapies in developed and developing countries. Discover what success is possible.
Our analyses show you individual revenue forecasts to 2025 for five regional markets: • United States • Japan • European Union • Asia Pacific • Rest of world.
There you discover progress and outlooks. You assess the nanomedical industry’s future – needs, developments, demands and their meaning. Our work explains, exploring issues affecting nanotechnological companies, influencing their work, results and potentials.
Forces affecting the nanopharma business – what shapes its present and future? Our new report discusses pressures, opportunities and other events affecting the nanopharmaceutical industry and market from 2015, including these influences: • Prominent nanomedicine companies by region – leading players • Systems used in nanotechnology-enabled drug delivery • Applications in therapeutics, implants, diagnostics and theranostics • Nanoparticles – liposomes, polymers, quantum dots, superparamagnetic iron oxide (SPIO), carbon nanotubes and nanoshells • Nanoparticle function, targeting, surface conjugation, improved bioavailability, tunability and controlled release systems • Investments, infrastructure, networks and collaborations, as well as outlooks for regulatory guidelines and harmonisation.
Our survey also discusses research and development in nanomedicine, in particular for these product candidates: • DermaVir (Genetic Immunity) • CRLX101 (Cerulean Pharma) • CPX-351 (Celator Pharma) • NC-6004 (NanoCarrier) • NK-105 (Nippon Kayaku) • NK-012 (Nippon Kayaku) • SGT-53 (SynerGene Therapeutics) • BIND-014 (BIND Biosciences) • ThermoDox (Celsion) • ADI-PEG 20 (Polaris).
You assess the nanomedicine industry’s strengths, weaknesses, opportunities and threats. That way you explore what restricts and stimulates companies, seeing what is possible.
Avoid falling behind. With our investigation you discover what the future holds for nano-enabled drugs, seeing prospects for their designers, producers and sellers.
Leading companies and overall 2017 revenue prediction From 2015, product launches using nanotechnology hold great potential for investments, demand and sales. Our study predicts the world market for nanopharmaceuticals will reach $130bn in 2017, with strong revenue expansion from 2015 to 2025. Explore the potentials.
Our work assesses nanopharma technologies, products and companies holding the best prospects. You see what is possible for technological advances and revenue expansion.
Those analyses cover these companies and other developers, producers, marketers and technology suppliers: • Sanofi • BIND Therapeutics • Merck • Pfizer • Cerulean Pharma • Selecta Biosciences.
And you assess these nanopharma specialists, among others: • Nanobiotix • Magforce • Celgene • Celsion Corporation • Nanocarrier.
You also examine three interviews with authorities in these organisations: • Swiss Federal Laboratories for Materials Science and Technology • Rexahn Pharmaceuticals • Cristal Therapeutics.
From 2015 there will arise many opportunities. Our work shows you commercial possibilities for those novel drug technologies, helping you stay ahead in knowledge and succeed.
Ways Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025 helps In the following main ways, our investigation helps your research, analyses, decisions, proposals and presentations: • Revenues for nanopharma to 2025 at overall world level and for 6 submarkets and 13 products – find outlooks for R&D, production and sales • Forecasts to 2025 for 5 regional markets – assess leading countries and regions for potential revenues, seeing what progress is possible • Prospects for established competitors and rising companies – explore portfolios, results, strategies, technologies and outlooks for success • Analysis of what encourages and restrains the nanomedicine industry – investigate challenges, strengths and competition affecting revenues and profits • Interviews with authorities – discover what other experts think, say and do, helping you stay ahead in technological, medical and commercial insight.
That study – by Visiongain’s in-house analysts in the UK – gives knowledge to help your work, to spare you hassle and save time. You gain data leading companies depend on.
Information found nowhere else, benefiting your authority on pharma nanotechnology Our survey gives independent analysis. There you gain competitive intelligence found only in our report, seeing where commercial prospects are most rewarding.
With our data you are less likely to fall behind in information or miss opportunity. Discover there how to benefit your searches, analyses, plans and decisions, also saving time and helping your influence.
So explore the future of nanomedicine. In our investigation you find data, trends, opportunities and multilevel sales predictions. Stay ahead by requesting our new report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the Nanomedicine Industry and Market 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by this Analysis 1.5 Who Is This Study For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQs) 1.8 Some Associated Reports 1.9 About Visiongain
2. Introduction to Nanomedicine 2.1 Nanotechnology – Definition 2.2 Nanomedicine – Size Should Not be the Main Definition 2.3 Nanotechnology – Solutions and Improvements in Medicine 2.4 Nanomedicine – Types of Applications 2.4.1 Drug Delivery 2.4.2 Nanodrugs 2.4.2.1 Nanoparticles – Combinations of Three Dimensions 2.4.2.1.1 Liposomes 2.4.2.1.2 Polymers 2.4.2.1.3 Quantum Dots 2.4.2.1.4 Superparamagnetic Iron Oxide (SPIO) 2.4.2.1.5 Carbon Nanotubes 2.4.2.1.6 Carbon Nanoshells 2.4.2.2 Nanoparticle Functionalisation 2.4.2.2.1 Targeting 2.4.2.2.2 Surface Conjugation 2.4.2.2.3 Improved Bioavailability 2.4.2.2.4 Tunability 2.4.2.2.5 Controlled Release 2.4.3 Implants 2.4.4 Diagnostics 2.4.4.1 Diagnostic Tools 2.4.4.2 Medical Instruments 2.4.4.3 Imaging Tools 2.4.4.4 Theranostics
3. Global Nanomedicine Market, 2015-2025 3.1 Revenue Forecasts of Nanomedicine by Therapeutic Area 3.1.1 Forecast of Nanomedicine for Oncology 2015-2025 3.1.2 Forecast of Nanomedicine for Cardiovascular Uses 2015-2025 3.1.3 Forecast of Nanomedicine for Anti-inflammatory Uses 2015-2025 3.1.4 Forecast of Nanomedicine for Neurology 2015-2025 3.1.5 Forecast of Nanomedicine for Anti-Infective 2015-2025 3.1.6 Forecast of Nanomedicine for Other Therapeutic Areas 2015-2025
5. Leading National Markets, 2015-2025 5.1 Nanomedicine – Leading Markets, 2014 5.2 The US Nanomedicine Market, 2015-2025 5.3 The Japanese Nanomedicine Market, 2015-2025 5.4 The EU Nanomedicine Market, 2015-2025 5.5 The Asia-Pacific Nanomedicine Market, 2015-2025 5.6 Rest of the World Nanomedicine Market, 2015-2025
8. Qualitative Analysis of the Nanomedicine Market, 2015 8.1 Room for Improvement 8.1.1 Safety and Toxicology Often Yet to be Determined 8.1.2 Establishment of Structures and Collaborations 8.1.3 Regulatory - The Need for Clear Guidelines and Harmonization
9. Research Interviews, 2015 9.1 Dr Peter Wick, Empa, the Swiss Federal Laboratories for Materials Science and Technology 9.1.1 Connecting the Key Players in the Nanomedical Sector in Europe 9.1.2 Nanomedicine Industry in Europe – In Need of an Infrastructure 9.1.3 EU-NCL: Bridging the Major Gaps and Challenges 9.2 Dr Peter D. Suzdak, CEO, Rexahn Pharmaceuticals 9.2.1 Precision-Targeted Therapy – Revolutionizes Cancer Treatment 9.2.2 RX-21101 – Included in NCL’s Preclinical Characterization Program 9.2.3 Rexahn’s NPDCS Technology – Next Generation Approach to Chemotherapy 9.2.4 Rexahn’s Polymer-Drug Conjugate – Improves Efficacy and Reduces Side Effects 9.3 Dr Joost Holthuis, CEO, Cristal Therapeutics, Netherlands 9.3.1 Nanomedicine Industry in Europe 9.3.2 CriPec Based Nanomedicines – Overcome the Drawbacks of Conventional Therapies 9.3.3 CriPec Platform – All the Best Features in a Single System 9.3.4 CriPec Docetaxel – Lead Candidate Product 9.3.5 In Development – CriPec Actively Targeted Nanoparticles Platform 9.3.6 Competitive Advantage Can be Achieved Through Partnering of Parties
10. Conclusions of the Research and Analysis 10.1 Nanotechnology Holds Great Promise in Healthcare 10.2 More Research Needed to Establish Safety 10.3 Harmonization in Definition and Guidelines
List of Tables Table 1.1 The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 2.1 Advantages of Nanotechnology in Medicine Table 2.2 Challenges and Solutions - NDDS Table 3.1 The Global Nanomedicine Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.2 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.1 Abraxane Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.2 Alimta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.3 Eligard Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.4 Copaxone Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.5 Rapamune Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.6 Neulasta Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.7 Cimzia Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.8 AmBisome Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.9 MIRCERA Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.10 Pegasys Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.11 Emend Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.12 Renagel Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 4.13 Ritalin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 5.1 Nanomedicine Market Revenues ($bn) for Leading Regions, 2014-2025 Table 5.2 Nanomedicine Market Share(%) by Leading Regions, 2014-2025 Table 5.3 Prominent Nanomedicine Companies in the US, 2014 Table 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 5.7 Prominent Nanomedicine Companies in the UK, 2014 Table 5.8 Prominent Nanomedicine Companies in Germany, 2014 Table 5.9 Prominent Nanomedicine Companies in France, 2014 Table 5.10 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 5.11 RoW Nanomedicine Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025 Table 8.1 Strengths, Weaknesses, Opportunities and Threats in the Nanomedicine Market, 2015
List of Figures Figure 1.1 Nanomedicine - Segmented by Application Figure 2.1 Applications of Nanotechnology in Diagnostics Figure 2.2 Applications of Nanotechnology in Therapeutics Figure 2.3 Systems Used in Nanotechnology-enabled Drug Delivery Figure 2.4 Market Shares of NDDS by System, 2014 Figure 2.5 NDDS: Market Drivers and Restraints, 2015-2025 Figure 2.6 Representation of Nanoparticles Figure 2.7 Combinations of Layers that Form Nanoparticles Figure 2.8 Nanoparticles: Market Drivers and Restraints 2015-2025 Figure 2.9 Implants: Market Drivers and Restraints, 2015-2025 Figure 2.10 Diagnostics: Market Drivers and Restraints, 2015-2025 Figure 2.11 Theranostics: Market Drivers and Restraints, 2015-2025 Figure 3.1 Global Nanomedicine Anti-Cancer Market: Revenue Forecast ($bn), 2015-2025 Figure 3.2 Applications of Nanotechnology in the Cardiovascular Therapeutic Area Figure 3.3 Global Nanomedicine CVD Market: Revenue Forecast ($bn), 2015-2025 Figure 3.4 Global Nanomedicine Anti-Inflammatory Market: Revenue Forecast ($bn), 2015-2025 Figure 3.5 Global Nanomedicine CNS Market: Revenue Forecast ($bn), 2015-2025 Figure 3.6 Global Nanomedicine Anti-Infectives Market: Revenue Forecast ($bn), 2015-2025 Figure 3.7 Global Nanomedicine Other Therapeutic Areas Market: Revenue Forecast ($bn), 2015-2025 Figure 4.1 Nanomedicine - Segmented by Application Figure 4.2 Proportions of Nano Products by Application, 2014 Figure 4.3 Proportions of Nano Products by Therapeutic Area, 2014 Figure 4.4 Abraxane Revenue Forecast ($bn), 2015-2025 Figure 4.5 Alimta Revenue Forecast ($bn), 2015-2025 Figure 4.6 Eligard Revenue Forecast ($bn), 2015-2025 Figure 4.7 Copaxone Revenue Forecast ($bn), 2015-2025 Figure 4.8 Rapamune Revenue Forecast ($bn), 2015-2025 Figure 4.9 Neulasta Revenue Forecast ($bn), 2015-2025 Figure 4.10 Cimzia Revenue Forecast ($bn), 2015-2025 Figure 4.11 AmBisome Revenue Forecast ($bn), 2015-2025 Figure 4.12 MIRCERA Revenue Forecast ($bn), 2015-2025 Figure 4.13 Pegasys Revenue Forecast ($bn), 2015-2025 Figure 4.14 Emend Revenue Forecast ($bn), 2015-2025 Figure 4.15 Renagel Revenue Forecast ($bn), 2015-2025 Figure 4.16 Ritalin Revenue Forecast ($bn), 2015-2025 Figure 5.1 Leading National Nanomedicine Markets by Share of Global Market (%), 2014 Figure 5.2 Leading National Nanomedicine Markets by Share of Global Market (%), 2019 Figure 5.3 Leading National Nanomedicine Markets by Share of Global Market (%), 2025 Figure 5.4 The US Nanomedicine Market: Revenue Forecast ($bn), 2015-2025 Figure 5.5 The Japanese Nanomedicine Market: Revenue Forecast ($bn), 2015-2025 Figure 5.6 EU Nanomedicine Market: Revenue Forecast ($bn), 2015-2025 Figure 5.7 Asia Pacific Nanomedicine Market: Revenue Forecast ($bn), 2015-2025 Figure 5.8 RoW Nanomedicine Market: Revenue Forecast ($bn), 2015-2025 Figure 7.1 Proportion of Products by Therapeutic Area in Clinical Trials, 2014 Figure 7.2 Products in Clinical Trials by Developmental Phase, 2014
Complete the form below to download your free sample pages for Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Nanopharmaceutical Industry and Market: Companies, Products, R&D and Revenue Forecasts 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.